Company Overview Summary

Business Focus

• The Company is a bio-aesthetics company specializing in developing, manufacturing, and marketing cosmetic skincare and haircare products.
• Additionally, the company's product pipeline included regenerative bone and tissue healing products, but further research and development on these has been paused.

Product Lines

• Cosmetic Skincare & Haircare Products:
  • Carmell SecretomeTM:
    • A proprietary formulation derived from allogeneic human platelets containing growth factors, proteins, and peptides.
    • Supports skin and hair regeneration by stimulating collagen production and tissue repair.
    • Utilizes a novel microemulsion formulation that avoids harmful excipients (e.g., sulfates, parabens, phthalates).
    • Products are developed for both retail (consumer) and professional (doctor/medspa) markets.
  • Elevai ExosomesTM:
    • Nano-sized extracellular vesicles containing growth factors, cytokines, peptides, and other molecules involved in healing.
    • Leverages human umbilical mesenchymal stem cell-derived exosomes obtained through cGMP manufacturing.
    • Designed for aesthetic enhancements, including skin and hair treatment support.
    • The product line includes:
      • Elevai EmpowerTM & Elevai EnfinityTM (post-treatment and ongoing care)
      • Elevai RenewTM Scalp Serum (launched in Q1 2025)

Current Operations

• Employees: 15 full-time employees.
• Customers: Primarily sell through three channels:
  • Direct-to-consumer via their online retail websites.
  • Business-to-business sales targeting physicians’ offices, medical spas, and other medically directed businesses.
  • Distributor channels (some exclusive or non-exclusive arrangements outside the US).
• Market Size:
  • Skincare and haircare markets valued around $280 billion (2022), growing at a 6.4% CAGR.
  • The aesthetic market is expanding 36% faster than pharmaceuticals.

Recent Business Activities

• 2025 Private Placement: Raised approximately $1.85 million from issuing shares at $0.23 per share.
• Elevai Acquisition: Completed an asset purchase of assets from PMGC Holdings, Inc. (Elevai) in January 2025, including products and related liabilities.
• Affecting Revenue:
  • The Elevai line generated ~$2.5 million in net sales for 2024.
• Name Change: Rebranded from "Carmell Corporation" to "Longevity Health Holdings, Inc." in March 2025.
• Leadership Transition:
  • Former CEO Kendra Bracken-Ferguson stepped down January 2025.
  • Rajiv Shukla, previously Chairman, became CEO in January 2025.

Financials

• Revenue (2024):
  • Total gross sales were $90,829.
  • Net sales were $50,318 after discounts.
  • The 2024 sales are from first five cosmetic skincare products launched in 2024.
• Net Income / Loss:
  • Net loss attributable to common stockholders: $10,368,261 in 2024.
  • The prior year (2023), net loss was $15,445,087.
  • A loss from continuing operations was $10,650,464 in 2024, compared to $16,205,252 in 2023.
  • The company also recognized a gain of $1,434,479 on sale of discontinued operations in 2024.
• Employees: 15 full-time employees as of March 27, 2025.
• Cash and Liquidity:
  • Cash balance at December 31, 2024: $157,139.
  • Negative working capital as of December 31, 2024: $4,921,151.

Strategic and R&D Activities

• Paused further research on regenerative bone and tissue healing products.
• Focused on near-term commercialization of skincare and haircare products.
• Launched initial skincare products in 2024 and additional products are expected to launch in the first half of 2025.
• Exploring licensing, out-licensing, and strategic transactions to improve liquidity.

Note: The company’s current activities are primarily centered on commercialization of cosmetic biotech products with no current production or sales of regenerative bone/tissue products.